The following supplemental cash flow information is provided with respect to certain cash payment and non-cash investing and financing activities (in millions): | | | | | | | | | | | | | | | Nine months ended September 30, | | | | 2026 | | 2025 | | | | Cash paid (refunded) for: | | | | | | | Interest paid | $ | 112 | | | $ | 109 | | | | | Income taxes (refunded) paid | (28) | | | 19 | | | | | Deferred sales inducements | 278 | | | 241 | | | | | Non-cash investing and financing activities: | | | | | | | | | | | | | Investment received as non-cash consideration for sale of F&G Life Re | 38 | | | — | | | | | Exchange of note receivable for incremental share in consolidated subsidiary | 36 | | | — | | | | | Investments transferred subject to reinsurance agreement | — | | | (500) | | | | | Change in proceeds of sales of investments available for sale receivable in period | (10) | | | (4) | | | | | Change in purchases of investments available for sale payable in period | 287 | | | 142 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|